PROFILE
The Company: Biona is a biotechnology Company with Chemical Facilities, working with
subcontractors. Biona developed ethical compounds for a huge market, which successfully passed
Animal Trials and are ready for Clinical Development.
The Product: LIBIDOR is a New Chemical Entity, affecting brain dopamine receptors of
patients with decreased libido, erectile dysfunction, anorgasmia, delayed ejaculation or diabetic
patients with sexual disorders. The compound is a small molecule, highly selective, with high
affinity to the required receptor, with no side effects, bioavailable, non-toxic, inexpensive
manufacturing (2 phases from 3 inexpensive chemicals), wide therapeutic window, easy and fast
clinical trials (one-dose administration). LIBIDOR acts as selective D4.4 activator, avoiding
side effects and is active on male and female alike.
The Market: Currently sexual dysfunction is treated by Viagra, Levitra and Cialis (~$6B in
2003). All three increase blood flow to penis, causing erection. They have systematic vascular
side effects and are applicable to men only. No one of these medications is connected to libido.
The population of the developed countries suffers from the decrease in libido due to:
 Age changes of men;
 Postmenopausal period of women;
 Wide administration of various medications (especially antidepressants);
 Stress factors of modern way of life, etc.
Within several years the existing drugs will become generic. LIBIDOR uses another mechanism
of action, active for wider market and can become a blockbuster after its approval.
The Team:
Volodia Voronel, VP Business Development, former VP CFO of SoluBest (drug delivery
company), VP BD and Strategy of Simplima, advisor to Minister of Industry & Trade
Dr. Vladimir Kogan, CTO, organic chemist, the inventor of the compounds
Dr. Andrei Matsaev, VP R&D, former VP R&D in Drug Development companies
Prof. John Finberg, Pharmacology, Technion - Israel Institute of Technology, developed Azilect
(the new ethical drug of Teva, approved in 2008)
Prof. Arie Shalev, Clinical Trials, Head of Psychiatry Dept in Hadassah Hospital
Dr. Alexander Tsimanis, expert in molecular biology, former Professor of Genetic Engineering
The Goal: The Company is looking to out-license the compound to a Pharma Company or to
locate investors for drug development effort (Clinical Trials until Phase II).
Volodia Voronel;
Email: volodia@voronel.net;
Phone: +972-52-3807608